191 related articles for article (PubMed ID: 23583476)
1. ¹⁸F-FDG-PET/CT in malignant mesothelioma.
Fuccio C; Spinapolice EG; Ferretti A; Castellucci P; Marzola MC; Trifirò G; Rubello D
Biomed Pharmacother; 2013 Jul; 67(6):539-42. PubMed ID: 23583476
[TBL] [Abstract][Full Text] [Related]
2. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
3. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Kitajima K; Doi H; Kuribayashi K
Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
[TBL] [Abstract][Full Text] [Related]
4. Loco-regional staging of malignant pleural mesothelioma by integrated
Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
[TBL] [Abstract][Full Text] [Related]
5. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
6.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
7. 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
Hall DO; Hooper CE; Searle J; Darby M; White P; Harvey JE; Braybrooke JP; Maskell NA; Masani V; Lyburn ID
Nucl Med Commun; 2018 Feb; 39(2):161-170. PubMed ID: 29300270
[TBL] [Abstract][Full Text] [Related]
8. Malignant peritoneal mesothelioma with lower extremity metastasis: PET/CT imaging.
Le BB; Nguyen BD
Clin Nucl Med; 2015 Jan; 40(1):e68-70. PubMed ID: 24830875
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
10. Pseudomesotheliomatous lung cancer mimicking mesothelioma on ¹⁸F-FDG PET/CT images: report of 2 cases.
Nakamori T; Kosuda S; Kyoto Y; Fujikawa A; Naoi Y; Nakamori Y
Jpn J Radiol; 2013 Aug; 31(8):542-5. PubMed ID: 23620108
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma.
Kandathil A; Subramaniam RM
Semin Nucl Med; 2022 Nov; 52(6):650-661. PubMed ID: 35738910
[TBL] [Abstract][Full Text] [Related]
12. High performance of F-fluorodeoxyglucose positron emission tomography and contrast-enhanced CT in a rapid outpatient diagnostic program for patients with suspected lung cancer.
Brocken P; van der Heijden HF; Dekhuijzen PN; Peters-Bax L; de Geus-Oei LF
Respiration; 2014; 87(1):32-7. PubMed ID: 23595051
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
[TBL] [Abstract][Full Text] [Related]
14. Multiple primary hepatic malignant mesotheliomas mimicking cystadenocarcinomas on enhanced CT and FDG PET/CT.
Dong A; Dong H; Zuo C
Clin Nucl Med; 2014 Jul; 39(7):619-22. PubMed ID: 23510896
[TBL] [Abstract][Full Text] [Related]
15. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
16. "PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma".
Lopci E; Kobe C; Gnanasegaran G; Adam JA; de Geus-Oei LF
Semin Nucl Med; 2021 Sep; 51(5):458-473. PubMed ID: 33993985
[TBL] [Abstract][Full Text] [Related]
17. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
Niccoli-Asabella A; Notaristefano A; Rubini D; Altini C; Ferrari C; Merenda N; Fanelli M; Rubini G
Clin Imaging; 2013; 37(6):1098-103. PubMed ID: 23932389
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
